Restructuring On The Table For FibroGen After Roxadustat Rejection

 
• By Alaric DeArment

As anticipated, the FDA issued a complete response letter for roxadustat. While the drug is expected to win EU approval, it is unclear if FibroGen and AstraZeneca will be willing to fund another trial.

Malekidneys-cancer
The FDA issued a complete response letter for FibroGen and AstraZeneca's roxadustat in anemia of chronic kidney disease • Source: Shutterstock

More from Strategy

More from Business